TCGA-78-7535-01A-11R-2066-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 45
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.310
- KRAS_SIGNALING_DN+0.290
- APICAL_SURFACE+0.210
- KRAS_SIGNALING_UP+0.210
- PANCREAS_BETA_CELLS+0.200
- MYOGENESIS+0.180
- ESTROGEN_RESPONSE_LATE+0.170
- ALLOGRAFT_REJECTION+0.160
- INFLAMMATORY_RESPONSE+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- PROTEIN_SECRETION-0.600
- UNFOLDED_PROTEIN_RESPONSE-0.580
- MYC_TARGETS_V2-0.530
- OXIDATIVE_PHOSPHORYLATION-0.470
- MITOTIC_SPINDLE-0.450
- MTORC1_SIGNALING-0.440
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- ANDROGEN_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.932 |
| 2 | SRR1313426 | GTEX | — | 0.929 |
| 3 | SRR1459423 | GTEX | — | 0.925 |
| 4 | SRR1340301 | GTEX | — | 0.919 |
| 5 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.919 |
| 6 | SRR1382956 | GTEX | — | 0.918 |
| 7 | SRR1444876 | GTEX | — | 0.917 |
| 8 | BS_PQ7CQFYR | Ganglioglioma | — | 0.916 |
| 9 | SRR1456294 | GTEX | — | 0.916 |
| 10 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |